Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ENZY

(ENZY) (ENZY) Stock Price, News & Analysis

(ENZY) logo

About (ENZY) Stock (NASDAQ:ENZY)

Key Stats

Today's Range
$11.85
$11.85
50-Day Range
N/A
52-Week Range
$6.30
$12.35
Volume
N/A
Average Volume
120,557 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive ENZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ENZY) and its competitors with MarketBeat's FREE daily newsletter.

ENZY Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
32 top US cities to have a cat
See More Headlines

ENZY Stock Analysis - Frequently Asked Questions

(ENZY) (NASDAQ:ENZY) issued its quarterly earnings results on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. (ENZY)'s quarterly revenue was down 14.3% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that (ENZY) investors own include Caesarstone (CSTE), Laredo Petroleum (LPI), Allena Pharmaceuticals (ALNA), Camtek (CAMT), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB) and Aquinox Pharmaceuticals (AQXP).

Company Calendar

Last Earnings
5/17/2017
Today
11/07/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ENZY
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:ENZY) was last updated on 11/7/2024 by MarketBeat.com Staff
From Our Partners